Clinuvel Pharmaceuticals Ltd

Clinuvel Pharmaceuticals Limited announced the filing of a marketing authorisation dossier for its second pharmaceutical product, NEURACTHEL® Instant (tetracosactide), with national European regulators. This submission is part of the European decentralised procedure (DCP), aiming for commercialization as a prescription pharmaceutical in up to three initial key EU Member States. NEURACTHEL® Instant is a branded generic formulation of tetracosactide, a synthetic peptide analogue of ACTH. The company has identified key European Union Member States for launch based on market factors and existing commercial infrastructure. The global ACTH market is valued at approximately US$1.3 billion annually. Further submissions to other regulatory bodies, including the UK's MHRA and potentially the U.S. FDA, are under evaluation.

Clinuvel Pharmaceuticals provided an update on its VLRX-L controlled-release liquid injectable peptide formulation platform. Following promising pre-clinical data, the company is refining a candidate formulation that demonstrated a superior release profile over the targeted peptide delivery window. Further pre-clinical studies are planned for Q1 2027, with manufacturing scale-up being scoped for the platform, which initially focuses on melanocortin peptides.

Clinuvel Pharmaceuticals provided a commercial update on the emerging vitiligo market, comparing its SCENESSE® (afamelanotide) therapy with current standard of care (NB-UVB) and developing JAK inhibitors. The company highlighted SCENESSE®'s potential as a systemic repigmentation therapy for extensive vitiligo, noting its different mechanism of action compared to immune-suppressing JAK inhibitors. Clinuvel anticipates topline results from its CUV105 study in December 2026 and plans to start the pivotal CUV107 study in November 2026, alongside ongoing commercial preparations.

Clinuvel Pharmaceuticals provided an update on its SCENESSE® (afamelanotide) clinical program for vitiligo patients with darker skin. Topline results for the CUV105 study, which evaluates SCENESSE® with adjuvant narrowband ultraviolet B (NB-UVB), are expected in December 2026. The European Medicines Agency (EMA) reviewed the protocol for the pivotal Phase III CUV107 study, which is anticipated to begin recruitment in November 2026. The company aims to submit robust data for marketing authorization, building on existing approvals for SCENESSE® in erythropoietic protoporphyria.

Clinuvel Pharmaceuticals Limited filed a Form 6-K with the SEC, reporting the submission of an "Appendix 3H - Notification of cessation of securities" to the Australian Securities Exchange. This notification, dated July 27, 2026, indicates a change in the company's issued share capital and was attached as Exhibit 99.1 to the SEC filing.

Clinuvel Pharmaceuticals Ltd announced a strategic reorganization of its operations and workforce, effective January 1, 2027, which includes relocating its corporate headquarters to the United States. The company plans to reduce its global workforce by approximately 10%-20% and will focus its operational resources exclusively on the U.S. pharmaceutical market. This restructuring aims to strengthen regulatory engagement, commercial partnerships, and unlock deeper capital pools, aligning with the company's late-stage pipeline targeting the U.S. patient population.

Clinuvel Pharmaceuticals Limited announced that its American Depositary Share (ADS) is expected to commence trading on the Nasdaq Stock Market under the ticker symbol CUVL. This follows the SEC's declaration of effectiveness for the Company's 20-F Registration Statement and Nasdaq's approval. The existing over-the-counter American Depositary Receipt (ADR: CLVLY) will be upgraded from Level I to Level II, trading on the Nasdaq Global Select Market, which is expected to increase visibility among U.S. investors. The Company does not plan to raise capital or issue new shares with this upgrade.